Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
HIK Analyst Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HIK Stock 12 Month Forecast
Average Price Target
2,427.00p
▲(20.75% Upside)
| Highest Price Target2,650p | Average Price Target2,427p | Lowest Price Target2,000p |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Berenberg Bank
Reiterated
03/11/25
J.P. Morgan
Reiterated
03/07/25
Stifel Nicolaus
Reiterated
03/05/25
RBC Capital
Reiterated
02/27/25
Barclays
Reiterated
02/27/25
Morgan Stanley
Reiterated
02/12/25
Deutsche Bank
2,750p→3,100p
Buy
54.23%
Upside
Reiterated
11/25/24
Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Raised to GBP31 at Deutsche BankDeutsche Bank analyst Paul Cuddon raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP31.00 (from GBP27.50) while maintaining a Buy rating.
Citi
2,845p
Buy
41.54%
Upside
Assigned
08/09/24
Citi Issues a Buy Rating on Hikma Pharmaceuticals (HIK)
CFRA
2,200p→2,000p
Hold
-0.50%
Downside
Reiterated
04/26/24
Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Lowered to GBP20 at CFRACFRA analyst Wan Nurhayati lowered the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP20.00 (from GBP22.00) while maintaining a Hold rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Berenberg Bank
Reiterated
03/11/25
J.P. Morgan
Reiterated
03/07/25
Stifel Nicolaus
Reiterated
03/05/25
RBC Capital
Reiterated
02/27/25
Barclays
Reiterated
02/27/25
Morgan Stanley
Reiterated
02/12/25
Deutsche Bank
2,750p→3,100p
Buy
54.23%
Upside
Reiterated
11/25/24
Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Raised to GBP31 at Deutsche BankDeutsche Bank analyst Paul Cuddon raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP31.00 (from GBP27.50) while maintaining a Buy rating.
Citi
2,845p
Buy
41.54%
Upside
Assigned
08/09/24
Citi Issues a Buy Rating on Hikma Pharmaceuticals (HIK)
CFRA
2,200p→2,000p
Hold
-0.50%
Downside
Reiterated
04/26/24
Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Lowered to GBP20 at CFRACFRA analyst Wan Nurhayati lowered the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP20.00 (from GBP22.00) while maintaining a Hold rating.
HIK Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
0
0
0
0
0
Buy
4
5
5
6
7
Hold
1
2
2
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
7
7
9
9
Each month's total comprises the sum of three months' worth of ratings.
HIK Financial Forecast
HIK Stock Forecast FAQ
What is GB:HIK’s average 12-month price target, according to analysts?
Based on analyst ratings, Hikma Pharmaceuticals PLC’s 12-month average price target is 2,427.00p.
What is GB:HIK’s upside potential, based on the analysts’ average price target?
Hikma Pharmaceuticals PLC has 20.75% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Hikma Pharmaceuticals PLC a Buy, Sell or Hold?
Hikma Pharmaceuticals PLC has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
What is Hikma Pharmaceuticals PLC’s share price target?
The average share price target for Hikma Pharmaceuticals PLC is 2,427.00p. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,650.00p ,and the lowest forecast is 2,000.00p. The average share price target represents 20.75% Increase from the current price of 2,010p.
The highest analyst share price target is 2,650.00p ,and the lowest forecast is 2,000.00p. The average share price target represents 20.75% Increase from the current price of 2,010p.
What do analysts say about Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of Hikma Pharmaceuticals PLC?
To buy shares of GB:HIK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.